Pre-market hot trades in US stocks: Pershing Square down 7.71% in pre-market, poor IPO performance and Ackman's increased holdings failed to boost confidence

Hot Trades in Pre-Market US Stocks Pershing Square is down 7.71% in pre-market trading. Based on recent key news: On May 1, Pershing Square USA completed its initial public offering (IPO) with a total issuance scale of $5 billion. Despite the large fundraising scale, the market has performed poorly, with the stock price below the offering price, leading to a loss of investor confidence and a decline in stock price. Source: Benzinga On May 1, Ackman purchased a large amount of Pershing Square USA common stock, with a total transaction amount of $240 million. Although this move shows Ackman's confidence in the company's future, it failed to immediately boost the stock price. Source: SEC Filing On May 2, Pershing Square Inc.'s stock price rose 35.7%, while Pershing Square USA's stock price remained below the offering price. Investors were disappointed with the IPO's performance, leading to stock price volatility. Source: Benzinga The market's poor performance in the IPO has resulted in significant capital outflows. Top Gainers in Pre-Market US Stocks Credit Suisse High Yield Credit Fund is up 237.93% in pre-market trading, with no significant news recently. The trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and the specific reasons need further observation. Skycorp Solar is up 97.91% in pre-market trading. Based on recent key news: On May 1, Skycorp Solar Group Limited completed the acquisition of the remaining 56% equity of Nanjing Saisen Electric Power Co., Ltd. and raised $3 million through private placement from three institutional investors. This funding will be used to support operational funding needs and business expansion. Following this news, the stock price surged. On April 27, Skycorp Solar Group Limited received confirmation from Nasdaq that it had met the minimum bid requirements and continued to maintain its listing qualification. Previously, the company's stock price had been below $1 for 30 consecutive trading days, facing delisting risks. Following this news, the stock price significantly rebounded. On May 1, Skycorp Solar Group Limited issued a press release reminding investors not to overly rely on forward-looking statements and discussed other factors in the company's SEC filings. Nevertheless, market sentiment remains optimistic, driving the stock price up. The solar industry has performed strongly recently, with clear policy support. Rallybio is up 49.10% in pre-market trading. Based on recent key news: On May 4, Rallybio's stock price rose 34.9% in pre-market trading, reaching $12.69. UCB announced it would acquire Candid Therapeutics for $2.2 billion to strengthen its immunology product line Rallybio previously announced a merger with Candid, but before the transaction was completed, UCB intervened to acquire Candid. This news significantly boosted Rallybio's stock price. In March, Rallybio announced a merger with Candid, after which the company will retain the Candid name and trade under CDRX. According to the agreement, Rallybio shareholders will hold approximately 3.65% of the merged company, while Candid shareholders will hold about 96.35% of the shares. The news of this merger plan had a positive impact on Rallybio's stock price. J.P. Morgan analysts stated that UCB's acquisition of Candid is highly aligned with its immunology business strategy, and this analyst viewpoint further strengthened market confidence in Rallybio. Mergers and acquisitions in the immunology field are active, attracting significant market attention